[go: up one dir, main page]

WO2001029256A3 - Cephalic pain susceptibility marker - Google Patents

Cephalic pain susceptibility marker Download PDF

Info

Publication number
WO2001029256A3
WO2001029256A3 PCT/GB2000/004050 GB0004050W WO0129256A3 WO 2001029256 A3 WO2001029256 A3 WO 2001029256A3 GB 0004050 W GB0004050 W GB 0004050W WO 0129256 A3 WO0129256 A3 WO 0129256A3
Authority
WO
WIPO (PCT)
Prior art keywords
cephalic pain
individual
susceptibility marker
pain susceptibility
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/004050
Other languages
French (fr)
Other versions
WO2001029256A2 (en
Inventor
Ian James Purvis
Linda Catherine Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU79356/00A priority Critical patent/AU7935600A/en
Publication of WO2001029256A2 publication Critical patent/WO2001029256A2/en
Anticipated expiration legal-status Critical
Publication of WO2001029256A3 publication Critical patent/WO2001029256A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/101—Taqman
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method of diagnosting susceptibility to cephalic pain in an individual, which method comprises typing in a sample from the individual the insulin receptor gene region or insulin receptor protein of the individual and determining thereby whether the individual is susceptible to cephalic pain.
PCT/GB2000/004050 1999-10-19 2000-10-19 Cephalic pain susceptibility marker Ceased WO2001029256A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79356/00A AU7935600A (en) 1999-10-19 2000-10-19 Cephalic pain susceptibility marker

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924717.3A GB9924717D0 (en) 1999-10-19 1999-10-19 Diagnostic
GB9924717.3 1999-10-19

Publications (2)

Publication Number Publication Date
WO2001029256A2 WO2001029256A2 (en) 2001-04-26
WO2001029256A3 true WO2001029256A3 (en) 2002-06-13

Family

ID=10862998

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2000/004050 Ceased WO2001029256A2 (en) 1999-10-19 2000-10-19 Cephalic pain susceptibility marker
PCT/GB2000/004024 Ceased WO2001029255A2 (en) 1999-10-19 2000-10-19 Diagnostic test for cephalic pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004024 Ceased WO2001029255A2 (en) 1999-10-19 2000-10-19 Diagnostic test for cephalic pain

Country Status (5)

Country Link
EP (1) EP1226276A2 (en)
JP (1) JP2003512062A (en)
AU (2) AU1152001A (en)
GB (1) GB9924717D0 (en)
WO (2) WO2001029256A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1037301A (en) * 1999-10-19 2001-04-30 Glaxo Group Limited Therapy of cephalic pain
AU1036801A (en) * 1999-10-19 2001-04-30 Glaxo Group Limited Agent for treating cephalic pain
JP7107882B2 (en) * 2019-04-22 2022-07-27 ジェネシスヘルスケア株式会社 How to Determine Migraine Risk

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
EP0503440A1 (en) * 1991-03-08 1992-09-16 Glaxo Group Limited Compositions containing sumatriptan
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
EP0803570A1 (en) * 1994-05-12 1997-10-29 Otsuka Pharmaceutical Co., Ltd. Mutant human insulin receptor dna

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
EP0503440A1 (en) * 1991-03-08 1992-09-16 Glaxo Group Limited Compositions containing sumatriptan
EP0803570A1 (en) * 1994-05-12 1997-10-29 Otsuka Pharmaceutical Co., Ltd. Mutant human insulin receptor dna
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARBETTI F ET AL: "DETECTION OF MUTATIONS IN INSULIN RECEPTOR GENE BY DENATURING GRADIENT GEL ELECTROPHORESIS", DIABETES, NEW YORK, NY, US, vol. 41, no. 4, 1 April 1992 (1992-04-01), pages 408 - 415, XP000615530, ISSN: 0012-1797 *
KROOK A ET AL: "RAPID AND SIMULTANEOUS DETECTION OF MULTIPLE MUTATIONS BY POOLED AND MULTIPLEX SINGLE NUCLEOTIDE PRIMER EXTENSION: APPLICATION TO THE STUDY OF INSULIN-RESPONSIVE GLUCOSE TRANSPORTER AND INSULIN RECEPTOR MUTATIONS IN NON-INSULIN-DEPENDENT DIABETES", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 1, no. 6, 1992, pages 391 - 395, XP000939000, ISSN: 0964-6906 *
MORRIS B.: "Insulin receptor gene in hypertension", CLINICAL AND EXPERIMENTAL HYPERTENSION, vol. 19, no. (5 & 6), 1997, pages 551 - 65, XP001053711 *
NYHOLT D ET AL: "Familial typical migraine", NEUROLOGY, vol. 50, no. 5, May 1998 (1998-05-01), pages 1428 - 32, XP001053727 *
SPLIT W ET AL: "HEADACHES IN NON INSULIN-DEPENDENT DIABETES MELLITUS", FUNCTIONAL NEUROLOGY, CIC EDIZIONI INTERNATIONALI, ROME, IT, vol. 12, no. 6, November 1997 (1997-11-01), pages 327 - 332, XP001028137, ISSN: 0393-5294 *

Also Published As

Publication number Publication date
WO2001029256A2 (en) 2001-04-26
WO2001029255A2 (en) 2001-04-26
AU1152001A (en) 2001-04-30
GB9924717D0 (en) 1999-12-22
AU7935600A (en) 2001-04-30
EP1226276A2 (en) 2002-07-31
WO2001029255A9 (en) 2002-02-07
WO2001029255A3 (en) 2002-05-16
JP2003512062A (en) 2003-04-02

Similar Documents

Publication Publication Date Title
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
ZA200107497B (en) Methods for detection of nucleic acid polymorphisms using peptide-labeled oligonucleotides and antibody arrays.
AU4986700A (en) Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
AU2001283916A1 (en) Method and nucleic acids for the analysis of astrocytomas
AU3199699A (en) Modified nucleotides and methods useful for nucleic acid sequencing
WO2001040798A3 (en) Methods of using randomized libraries of zinc finger proteins for the identification of gene function
AU5671096A (en) Methods, nucleotide sequences and host cells for assaying ex ogenous and endogenous protease activity
WO2000012726A3 (en) Rationally designed heparinases derived from heparinase i and ii
WO1998021343A8 (en) Genes encoding telomerase proteins
AU6256896A (en) Methods for nucleic acid detection, sequencing, and cloning using exonuclease
AU2744200A (en) Determining protein function and interaction from genome analysis
IL118375A0 (en) Rhesus OB protein and DNA
AU6728000A (en) Novel g protein-coupled receptor protein and dna thereof
AU3354499A (en) Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
AU6458400A (en) Nucleic acid, polypeptides, assays, therapeutic methods and means
ZA200101737B (en) Nucleic acid molecules which code for enzymes with fructosyltransferase activity and use thereof.
AU5245900A (en) Novel protein and dna thereof
AU7000898A (en) Mouse lacking heart-muscle adenine nucleotide translocator protein and methods
ZA974286B (en) The spindly gene, methods of identification and use.
WO2001029256A3 (en) Cephalic pain susceptibility marker
AU7774391A (en) Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
WO2001077305A3 (en) Variants of the human amp-activated protein kinase gamma 3 subunit
WO2004050857A3 (en) Splice variant of human sodium iii channel (hnaiii18)
AU2136601A (en) Modified leukotoxin gene and protein
AU7846000A (en) Novel human lipase proteins, nucleic acids encoding them, and uses of both of these

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP